Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer's Disease: A Correlative Meta-Analysis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Neurofilament light (NFL) is a putative biomarker of neurodegeneration. This study evaluates the correlative association of NFL with Alzheimer’s disease (AD) indices. Relevant studies were identified after a literature search in electronic databases and study selection was based on pre-determined eligibility criteria. Correlation coefficients between NFL levels and important AD indices reported by individual studies were pooled as z-scores. Meta-regression analyses were performed to evaluate the relationships between important covariates. Data from 38 studies (age 68.3 years [95% confidence interval (CI): 65.7, 70.9]; 54 % [95%CI: 50, 57] females) were used. Meta-analyses of correlation coefficients reported by the included studies showed that NFL levels in blood and cerebrospinal fluid (CSF) correlated well (r=0.59 [95%CI: 0.45, 0.71]; p˂0.0001). NFL levels correlated with MMSE score (r=−0.345 [95%CI: −0.43, −0.25]; p=0.0001), and age (r=0.485 [95% CI: 0.35, 0.61]; p=0.00001). CSF NFL levels correlated with total tau (t-tau; r=0.39 [95%CI: 0.27, 0.50]; p=0.0001), phosphorylated tau (p-tau; r=0.34 [95%CI: 0.19, 0.47]; p=0.00001), and neurogranin (r=0.25 [95%CI: 0.12, 0.37]; p=0.001) but not with beta amyloid (Aβ) (r=0.00 [95%CI: −0.13, 0.12]; p=0.937). In meta-regression, MMSE scores were associated inversely with blood NFL (metaregression coefficient (MC) −0.236 [95% CI:−0.40, −0.072; p=0.008), and age (MC −0.235 [−0.36, −0.11]; p=0.001) and positively with CSF Aβ-42 (MC 0.017 [0.010, 0.023]; p=0.00001). NFL has good correlations with t-tau, and p-tau in CSF and CSF NFL levels correlates well with blood NFL levels. These results show that NFL can be a useful biomarker for improving diagnosis and predicting prognosis in AD patients especially if age weighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726 · cited 4×
“…et al., 2018; Sánchez-Valle et al., 2018; Steinacker et al., 2018; Vogt et al., 2018; Zerr et al., 2018; Ashton et al., 2019; Bos et al., 2019; Lleó et al., 2019; Marchegiani et al., 2019; Mattsson et al., 2019; Niikado et al., 2019) which were selected by following eligibility criteria (Figure 1).”
BackgroundMethodInfluentialZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · cited 3×
“…26 AD 67 ± 8 57.69 1,595 ± 1,005 32 ± 16 545 ± 226 659 ± 268 78 ± 34 Vogt et al., 2018 40 AD 71.9 ± 8.6 40 1,628 ± 935 722 ± 300 74.7 ± 27 Landqvist Waldö et al., 2013 20 AD 72 ± 10 65 415 ± 309 285 ± 92 630 ± 621.9 87 ± 58 Weston et al., 2017 48 AD-fam 40.5 ± 8.2 45.83 25 ± 12 Weston et al.,…”
InfluentialThe gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease
Vogt, N. M., Romano, K. A., Darst, B. F., Engelman, C. D., Johnson, S. C., Carlsson, C. M., Asthana, S., Blennow, K., Zetterberg, H., Bendlin, B. B., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0451-2 · Cited by 471
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
Weston, P. S. J., Poole, T., Ryan, N. S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I. B., Ahsan, R. L., Pemberton, H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004667 · Cited by 245
Neurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
Ashton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0649-3 · Cited by 172
Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127 · cited 2×
“…38 studies (Sjögren et al., 2001; de Jong et al., 2007; Pijnenburg et al., 2007; Bjerke et al., 2011; Kester et al., 2012; Gaiottino et al., 2013; Landqvist Waldö et al., 2013; Skillbäck et al., 2013; Evered et al., 2016; Melah et al., 2016; Fialova et al., 2017; Howell et al., 2017; Jensen et…”
BackgroundInfluentialCSF neurofilament proteins in the differential diagnosis of dementia
de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107326 · Cited by 120
Serum neurofilament light chain in behavioral variant frontotemporal dementia
Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., von Arnim, C. A. F., Barthel, H., Danek, A., Fassbender, K., Fliessbach, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006318 · Cited by 116
Plasma neurofilament light chain levels in Alzheimer’s disease
Zhou, W., Zhang, J., Ye, F., Xu, G., Su, H., Su, Y., & Zhang, X. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.04.027 · Cited by 95
Jensen, C. S., Portelius, E., Høgh, P., Wermuth, L., Blennow, K., Zetterberg, H., Hasselbalch, S. G., & Simonsen, A. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.007 · Cited by 36
Cited by
Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 290
Chhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60
Lim, B., Fowler, C., Li, Q.-X., Rowe, C., Dhiman, K., Gupta, V. B., Masters, C. L., Doecke, J. D., Martins, R. N., Collins, S., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135078 · Cited by 10
Disrupted structural connectivity in ArcAβ mouse model of Aβ amyloidosis
Al-Amin, M. M., Grandjean, J., Klohs, J., & Kim, J. (2020) · doi:10.1101/2020.04.27.064634 · Cited by 2
“The concentrations of NFL is increased both in the plasma (Lin et al., 2018) and CSF (Jin et al., 2019, Zetterberg et al., 2016) in AD.”
BackgroundInfluential
Metadata
- Authors
- Jin, M., Cao, L., & Dai, Y.-P.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-09-13
- Volume
- 11
- Pages
- 254-254
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2971269986
- Cited by
- 102
- References
- 16
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.